EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial

Geert V T Roozen iD, Roos van Schuijlenburg iD, Annefleur D O Hensen iD, Jan Pieter R Koopman iD, Olivia A C Lamers, Fiona J A Geurten, Jeroen C Sijtsma iD, Els Baalbergen, Jacqueline J Janse, Séverine Chevalley-Maurel iD, Chanel M Naar iD, Sascha Bezemer und 14 weitere

Nature Medicine · 2025-01 · 31 (1) · 218-222

DOI: 10.1038/s41591-024-03347-2 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Nature Medicine, online erschienen am 03.01.2025. Verfasst von Geert V T Roozen und 25 weiteren Autor:innen. Beteiligte Einrichtung: Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Insect Bites and Stings, Malaria Vaccines, Malaria, Falciparum, Plasmodium falciparum. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw (Netherlands Organisation for Health Research and Development), EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Scienc….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malaria vaccines consisting of metabolically active Plasmodium falciparum ( Pf ) sporozoites can offer improved protection compared with currently deployed subunit vaccines. In a previous study, we demonstrated the superior protective efficacy of a three-dose regimen of late-arresting genetically attenuated parasites administered by mosquito bite (GA2-MB) compared with early-arresting counterparts (GA1-MB) against a homologous controlled human malaria infection. Encouraged by these results, we explored the potency of a single GA2-MB immunization in a placebo-controlled randomized trial. Primary outcomes were safety and tolerability, time-to-parasitemia and protective efficacy. Humoral and cellular immunological results were considered secondary outcomes. Here we report the safe administration of GA2-MB with no breakthrough malaria and sterile protection in nine of ten participants at 6 weeks after a single immunization with 50 GA2-infected mosquitoes, compared with none of five mock-immunized participants, against a homologous controlled human malaria infection. Immunization increased circulating Pf -specific polyfunctional effector memory CD4 + T cells coexpressing tumor necrosis factor and interleukin-2. This unprecedented 90% protective efficacy after a single low-dose immunization holds great promise for the potency of GA2 immunization. Future studies should demonstrate whether GA2 is similarly efficacious in pre-exposed populations and whether the favorable safety profile reported here holds up in larger groups. ClinicalTrials.gov registration: NCT05468606 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insect Bites and StingsMalaria VaccinesMalaria, FalciparumPlasmodium falciparumAdolescentAdultAnimalsFemaleHumansMaleMiddle AgedYoung AdultCD4-Positive T-LymphocytesCulicidaeImmunizationSporozoitesVaccines, Attenuated

Substanzen

Malaria VaccinesVaccines, Attenuated

Autor:innen und Institutionen

  • Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
  • Medical Technology and Prototyping, Leiden University Medical Center, Leiden, The Netherlands.
  • Center for Cell and Gene Therapy, Leiden University Medical Center, Leiden, The Netherlands.
  • Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
  • Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands. m.roestenberg@lumc.nl.

ORCID-Profile: Geert V T Roozen, Roos van Schuijlenburg, Annefleur D O Hensen, Jan Pieter R Koopman, Jeroen C Sijtsma, Séverine Chevalley-Maurel, Chanel M Naar, Pauline Meij, Mara S Tihaya, Emil Colstrup, Els Wessels, Rajagopal Murugan, Meta Roestenberg

Förderung

  • ZonMw (Netherlands Organisation for Health Research and Development)
  • EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Scienc…

Zitieren

APA

Roozen, G. V. T., van Schuijlenburg, R., Hensen, A. D. O., Koopman, J. P. R., Lamers, O. A. C., Geurten, F. J. A., Sijtsma, J. C., Baalbergen, E., Janse, J. J., Chevalley-Maurel, S., Naar, C. M., Bezemer, S., Kroeze, H., van de Stadt, H. J. F., de Visser, B., Meij, P., Tihaya, M. S., Colstrup, E., Iliopoulou, E., …, & Roestenberg, M. (2025). Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial. Nature Medicine, 31(1), 218-222. https://doi.org/10.1038/s41591-024-03347-2

Vancouver

Roozen GVT, van Schuijlenburg R, Hensen ADO, Koopman JPR, Lamers OAC, Geurten FJA, et al. Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial. Nature Medicine. 2025;31(1):218-222. doi:10.1038/s41591-024-03347-2

BibTeX
@article{Roozen2025,
  author = {Roozen, Geert V T and van Schuijlenburg, Roos and Hensen, Annefleur D O and Koopman, Jan Pieter R and Lamers, Olivia A C and Geurten, Fiona J A and Sijtsma, Jeroen C and Baalbergen, Els and Janse, Jacqueline J and Chevalley-Maurel, Séverine and Naar, Chanel M and Bezemer, Sascha and Kroeze, Hans and van de Stadt, Huybert J F and de Visser, Bram and Meij, Pauline and Tihaya, Mara S and Colstrup, Emil and Iliopoulou, Eva and de Bes-Roeleveld, Helena M and Wessels, Els and van der Stoep, M Y Eileen C and Janse, Chris J and Murugan, Rajagopal and Franke-Fayard, Blandine M D and Roestenberg, Meta},
  title = {Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial},
  journal = {Nature Medicine},
  year = {2025},
  volume = {31},
  number = {1},
  pages = {218--222},
  doi = {10.1038/s41591-024-03347-2}
}
Kostenlos starten →